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Abstract
 
Peripheral immune tolerance is believed to be induced by the processing and presentation of
self-tissues that die during physiologic tissue turnover. To examine the mechanism that medi-
ates tolerance, we injected mice with dying syngeneic TAP
 
 
 
/
 
 
 
 splenocytes loaded with small
amounts of the protein antigen, ovalbumin (OVA). After ingestion and presentation of cell-
associated OVA by the CD8
 
 
 
 subset of dendritic cells in situ, large numbers of antigen-reac-
tive, CD8
 
 
 
 T cell receptor (TCR) transgenic T lymphocytes were driven into cell cycle, but
then the T cells were deleted. The animals were also tolerant to challenge with OVA in com-
plete Freund’s adjuvant. An agonistic anti-CD40 monoclonal antibody was then administered
together with the OVA-loaded splenocytes, so that the dendritic cells in the recipient mice
would mature. In contrast to observations made in the steady state, the antigen-reactive T cells
expanded in numbers for 1–2 wk and produced large amounts of interleukin 2 and interferon
 
 
 
, while the animals retained responsiveness to antigen rechallenge. The specific tolerance that
develops when dendritic cells process self tissues in the steady state should prevent or reduce
the development of autoimmunity when dying cells are subsequently processed during infection.
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Introduction
 
Infection is frequently accompanied by cell death, and dying
cells are efficiently processed and presented to T lympho-
cytes by dendritic cells (DCs; for a review, see reference 1).
As a result, during infection there will be simultaneous pre-
sentation of self and foreign microbial antigens, creating the
potential for autoimmunity (2, 3). The risk of autoimmu-
nity is lessened by central or thymic tolerance. In the thy-
mus, autoreactive T cells are deleted or negatively selected
upon encounter of self-antigens, including self-antigens pre-
sented by thymic DCs (4, 5). However, central tolerance is
incomplete, and autoreactive T cells can escape negative se-
lection (6). In addition, some self-antigens do not access the
thymus (7) while others may be expressed later in life, after
the T cell repertoire has formed. Therefore, central toler-
ance needs to be buttressed by peripheral mechanisms (8, 9).
It has been proposed that DCs induce peripheral tolerance
by capturing cells that normally die during cell turnover (2,
3, 10, 11). Although it is known that DCs can capture dead
cells in vivo (10, 12), it remains to be shown that tolerance
ensues as a result of the ingestion of self-tissues.
To determine if antigens expressed in dying cells can in-
duce tolerance in vivo, we loaded a test protein OVA into
the cytoplasm of syngeneic cells under hyperosmotic con-
ditions (13). This osmotic shock also induces cell death,
and when the treated splenocytes are injected intrave-
nously, they are captured and presented by host CD8
 
 
 
DCs (12). By injecting OVA loaded but TAP
 
 
 
/
 
 
 
 cells,
which could not directly present OVA, we aimed to limit
the presentation of dying cells to recipient DCs in situ. In
addition, we used a polyclonal anti-OVA reagent to quan-
tify the levels of OVA protein within a single dose of the
injected TAP
 
 
 
/
 
 
 
 splenocytes. The amount of OVA was
small, 
 
 
 
150 ng, confirming the experience of others (14).
Nevertheless we will show that, as long as one studies DCs
and T cells in vivo in the steady state, without further ma-
nipulation, profound systemic tolerance develops after pre-
sentation of OVA from dying cells.
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Materials and Methods
 
Mice.
 
C57BL/6 (CD45.2) and TCR transgenic F5 mice,
specific for hemagglutinin peptide presented on H-2K
 
b
 
, were
from Taconic and TAP
 
 
 
/
 
 
 
 mice from The Jackson Laboratory.
OT-I TCR transgenic mice, specific for OVA peptide (SIIN-
FEKL) in the context of H-2K
 
b
 
, were provided by Dr. F. Car-
bone (University of Melbourne, Parkville, Victoria, Australia).
To obtain CD45.1
 
 
 
 OT-I cells, OT-I mice were crossed to
CD45.1
 
 
 
 B6.SJL-
 
Ptprc
 
a
 
 (Taconic), and F
 
1
 
 mice tested for expres-
sion of V
 
 
 
5.1/5.2
 
 and CD45.1. Mice were maintained in specific
pathogen-free conditions and studied at 6–8 wk according to in-
stitutional guidelines.
 
Abs and Reagents.
 
Rat mAbs for MHC class II (TIB120, M5/
114.15.2), CD205 (HB290, DEC-205), granulocytes (RB6–8C5,
Gr-1), B220 (TIB146, RA3–3A1), F4/80 (HB198), and CD8
(TIB211, 3.155) were from the American Type Culture Collec-
tion. FITC-anti-H-2K
 
b
 
, I-A
 
b
 
, CD25, CD40, CD80, CD86,
PE-conjugated anti-CD8
 
 
 
, CD11b, CD11c, CD44, CD45.1,
CD62L, CD69, Cy-Chrome
 
®
 
CD8, V
 
 
 
5.1
 
 
 
5.2
 
, V
 
 
 
2
 
, and V
 
 
 
11
 
, bi-
otinylated anti-CD119 and IFN-
 
 
 
, and allophycocyanin (APC)-
streptavidin were from BD Biosciences. Anti-CD11c, CD8
microbeads were from Miltenyi Biotec. Sheep anti–rat IgG con-
jugated to magnetic beads were from Dynal. Other reagents were
RPMI 1640 (GIBCO BRL), FCS (GIBCO BRL), CFA (Difco
Labs), carboxyfluorescein diacetate, succinimidyl ester (CFSE;
Molecular Probes), ACK buffer (Biosource International),
30% BSA solution (Sigma-Aldrich), and OVA tested to have
 
 
 
20 pg endotoxin/mg protein (Seikagaku Corporation), and for
ELISPOT and ELISA assays, ABC kit (Vector Laboratories) and
DAB (Dako).
 
Cell Preparations.
 
Spleen DCs were positively selected by
anti-CD11c microbeads
 
®
 
 from collagenase-digested low-density
cells (12). CD8
 
 
 
 OT-I T cells were prepared from meshed cell
suspensions of lymph nodes and spleen by depleting B220, CD4,
F4/80, MHC class II, and NK1.1-expressing cells using sheep
anti–rat IgG Dynabeads
 
®
 
. Splenocytes or T cells were suspended
at 10
 
7
 
/ml in PBS and incubated with CFSE at concentrations of
5 
 
 
 
M for 10 min at 37
 
 
 
C, and washed once with PBS supple-
mented with 0.1% FCS and twice with PBS. Antigen-loaded
cells were prepared by osmotic shock. In brief, 15 
 
 
 
 10
 
7
 
 spleno-
cytes were washed in RPMI twice, and resuspended in 1 ml of
hypertonic medium (0.5 M sucrose, 10% wt/vol polyethylene
glycol 1000, and 10 mM Hepes in RPMI 1640, pH 7.2) contain-
ing 10 mg/ml OVA, or HEL control protein, for 10 min at
37
 
 
 
C. 13 ml of prewarmed hypotonic medium (40% H
 
2
 
O, 60%
RPMI 1640) was added, and the cells incubated for an additional
2 min at 37
 
 
 
C. Immediately after the incubation, the cells were
spun, washed twice with ice-cold PBS, and injected into mice as
a source of dying cells
 
Adoptive Transfer, Administration of Cell-associated Antigen, and
Antigenic Challenge In Vivo.
 
3 
 
 
 
 10
 
6
 
 CFSE-labeled transgenic
OT-I T cells (15) in PBS were injected intravenously in 0.2 ml.
1 d later, the mice received intravenously 25 
 
 
 
 10
 
6
 
/0.1 ml of an-
tigen-loaded cells with or without 100 
 
 
 
g of agonistic anti-CD40
mAb intraperitoneally (FGK 45.5; a gift of Dr. T. Rolink, Basel
Institute for Immunology, Basel, Switzerland). T cell activation
was then monitored with flow cytometry. To test for tolerance of
the injected TCR-transgenic T cells, mice were given 0.3 
 
 
 
 10
 
6
 
OT-I T cells 1–2 d before the injection of osmotically shocked
splenocytes, followed by a challenge with OVA emulsified in
CFA at 10 
 
 
 
g/25 
 
 
 
l into the front footpads 9 d later. Alterna-
tively, mice were given two doses of splenocytes 6 d apart, and
challenged 9 d after the second dose.
 
Flow Cytometry.
 
To examine uptake of CFSE-labeled apop-
totic cells (12), low-density splenocytes were stained with
CD11c-PE and CD8
 
 
 
-Cy-Chrome™, and DCs monitored as
CD11c
 
 
 
 cells on a FACSCalibur™, analyzed with CELLQuest™
program (Becton Dickinson) or FlowJo (Tree Star Software). To
assess DC maturation, low-density splenocytes were stained with
PE-CD11c, CD8-Cy-Chrome™ in combination with FITC-
labeled mAbs against costimulatory molecules (CD40, 80, and 86)
or with biotinylated mAbs for CD119 followed by streptavidin-
APC. Prior to staining, cells were incubated with 2.4G2 mAb on
ice for 15 min to prevent nonspecific binding of mAbs. All proce-
dures were performed using cold PBS containing 2% FCS and 5
mM EDTA. To monitor OT-I cell proliferation and activation,
single cell suspensions of spleen or lymph nodes were prepared
from mice injected with CFSE-labeled OT-I T cells. The latter
were identified with CD8
 
 
 
-Cy-Chrome™, biotinylated anti-
CD45.1 plus streptavidin-APC
 
 
 
in combination with PE-mAbs.
For intracellular cytokine staining, lymphocytes were stimulated
in vitro with 500 ng/ml OVA peptide (SIINFEKL) in the pres-
ence of 5 
 
 
 
g/ml brefeldin A (Sigma-Aldrich) at 37
 
 
 
C for 4 h.
The cells were first stained with CD8
 
 
 
-Cy-Chrome™
 
 
 
and bio-
tinylated CD45.1 plus streptavidin-APC, fixed and permeabilized
(cytofix/cytoperm buffer from BD Biosciences), and then stained
with PE-conjugated anti–IL-2 or IFN-
 
 
 
 mAbs.
 
Quantitation of Cell-associated OVA.
 
Aliquots of OVA-
shocked splenocytes were lysed in SDS sample buffer and trans-
ferred to PVDF membranes (Immobilon P; Millipore) for stain-
ing with HRP-conjugated polyclonal rabbit anti-OVA (Research
Diagnostics, Inc.) and ECL visualization (Hyperfilm ECL; Amer-
sham Biotech). Signals were quantified relative to known
amounts of OVA protein added to splenic cell lysates.
 
Proliferation and ELISPOT Assays.
 
To assess presentation of
the captured antigens, isolated APCs were 
 
 
 
-irradiated at 15 Gy,
and mixed in graded dose with 2 
 
 
 
 10
 
5
 
 TCR-transgenic T cells
in 200 
 
 
 
l of RPMI supplemented with 5% FCS, 50 
 
 
 
M 2-mer-
captoethanol, 100 
 
 
 
g/ml streptomycin, and 100 U/ml penicillin
G (complete medium) in 96-well flat-bottom culture plates. 
 
3
 
H-
TdR was added at 38–48 h. For T cell proliferation and ELISPOT
assays of systemic immunity in adoptive transfer recipients, synge-
neic splenocytes pulsed for 1 h with 500 ng/ml SIINFEKL pep-
tide were used as APCs after extensive washing with complete
medium. Graded doses were then cultured with 2 
 
 
 
 10
 
5
 
 CD8
 
 
 
 T
cells in 96-well culture plates or ELISPOT plates coated with
anti–IFN-
 
 
 
. Proliferation was determined as 
 
3
 
H-TdR uptake be-
tween 40–50 h. For IFN-
 
 
 
 production, ELISPOT plates were in-
cubated for 36 h and biotinylated anti–IFN-
 
 
 
–specific mAb for
detection was added followed by streptavidin-HRP after exten-
sive washing. Then, the frequency of IFN-
 
 
 
–producing cells was
visualized by adding DAB as a HRP substrate.
 
Results
 
Recipient Spleen DCs in the Steady State Present OVA Asso-
ciated with Injected TAP
 
 
 
/
 
  
 
Dying Cells.
 
To verify that dy-
ing TAP
 
 
 
/
 
 
 
 cells were captured by recipient CD8
 
 
 
 DCs,
the splenocytes were labeled with CFSE and injected into
wild-type C57BL/6 and TAP
 
 
 
/
 
 
 
 mice. DCs from both
strains of mice were comparably active in ingesting the dy-
ing cells (Fig. 1 A, arrows), but only wild-type DCs were
able to present antigen to OVA-specific, OT-I, TCR 
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transgenic T cells (Fig. 1 B). To monitor antigen presenta-
tion in vivo, CFSE-labeled OT-I T cells were adoptively
transferred into C57BL/6 hosts that were then injected
with OVA/TAP
 
 
 
/
 
 
 
 shocked cells. Cell proliferation began
at day 2, where it was restricted to the spleen rather than
lymph node (Fig. 1 C, arrow), consistent with the fact that
spleen but not lymph node DCs take up injected dying
cells (12). The proliferation was much more extensive by
day 3 (Fig. 1 D, black arrow). When we injected spleno-
cytes from wild-type rather than TAP
 
 
 
/
 
 
 
 mice, then direct
presentation of OVA was observed even in TAP
 
 
 
/
 
 
 
 recip-
ients, but this direct presentation was less efficient (Fig. 1
D, white arrow). To restrict presentation of dying cells to
the recipient DCs, rather than the injected cells, we always
injected OVA/TAP
 
 
 
/
 
 
 
 shocked cells into wild-type mice.
The specificity of OT-I cell proliferation was evident
when we injected mixtures of OT-I with F5 TCR trans-
genic T cells specific for an influenza peptide presented on
H-2D
 
b
 
. The F5 T cells did not proliferate in mice re-
sponding to OVA (Fig. 1 E). Thus, injection of small
amounts of OVA protein in TAP
 
 
 
/
 
 
 
 shocked cells leads to
efficient antigen presentation on MHC class I products of
recipient DCs.
 
An Injection of Dying Cells in the Steady State Does Not
Lead to DC Maturation In Vivo.
 
To determine whether an
injection of dying cells induces phenotypic changes in
DCs, we examined a number of DC cell surface antigens
(Table I). Neither the CD8
 
 
 
 (that capture the injected dy-
ing cells) nor the CD8
 
 
 
 DC subsets showed alterations in
surface molecules known to be up-regulated upon terminal
differentiation or maturation of DCs (16), i.e., MHC class
II, CD40, 80, and 86. In contrast, each molecule was up-
regulated if the injection of osmotically shocked cells was
followed by FGK45, an agonistic anti-CD40 antibody (Ta-
ble I). The response of the CD8
 
 
 
 DCs to anti-CD40 was
comparable whether or not the DCs were exposed to dy-
ing cells (data not depicted). Interestingly, the CD119
IFN-
 
 
 
 receptor was down-regulated upon DC maturation
with anti-CD40 (Table I). Thus, the uptake of dying cells
is only accompanied by DC maturation if an additional
stimulus like anti-CD40 is also administered.
 
Presentation of Dying Cells in the Steady State Leads to
CD8
 
 
 
 T Cell Proliferation, but Anti-CD40 Stimulation Is Re-
quired for High Level Cytokine Formation and Homing Receptor
Changes.
 
To assess the early physiologic consequences of
presentation of dying cells in the absence or presence of a
Figure 1. Spleen DCs in the
steady state capture apoptotic
cells and present cell-associated
OVA to CD8  OT-I T cells in a
TAP-dependent manner. (A)
Uptake (arrows) by the CD8 
subset of CD11c  DCs, 3 h
after injection of CFSE-labeled
TAP /  splenocytes, loaded
with OVA during an osmotic
shock. (B) As in A, but CD11c 
and CD11c  fractions of spleen
low density cells from B6 or
TAP /  were added in graded
doses to 2   105 purified CD8 
OT-I T cells; T cell proliferation
was measured by 3H-TdR up-
take at 40–50 h. (C) Proliferation
3    106 CFSE-labeled, CD8 
OT-I T cells (arrow) 2 d after
intravenous injection of TAP / 
splenocytes loaded with either
HEL or OVA protein in spleen
and subcutaneous lymph nodes.
(D) As in C, but proliferation
was monitored 3 d after different
splenocytes were injected into
the indicated recipients (top la-
bels). (E) In response to OVA-
loaded splenocytes, CFSE-
labeled, OVA-specific OT-I T
cells (V 2V 5) proliferate at day
3, but not 2F5 influenza-specific
T cells (V 11). A–D are repre-
sentative of at least three experi-
ments and E, two experiments.1094 DC-induced Peripheral Tolerance After Uptake of Dying Cells
CD40 maturation stimulus, we examined OT-I responses
in the spleen 3 d later. In the absence of CD40 stimulation,
the proliferating T cells did not up-regulate CD25 IL-2 re-
ceptor nor down-regulate CD62L lymph node homing se-
lectin (Fig. 2 A, black arrows). Both CD25 and CD62L
changed in expression when OVA-loaded TAP /  spleno-
cytes were coadministered with anti-CD40 (Fig. 2 A,
white arrows). Proliferating OT-I T cells were also found
in lymph nodes of mice given splenocytes in the absence of
anti-CD40, as these T cells could home there via CD62L
(right side of Fig. 2 A, black arrow). Consistent with the
down-regulation of CD62L, a homing receptor, proliferat-
ing OT-I cells were not found in the lymph nodes 3 d after
anti-CD40 triggering (Fig. 2 A). Furthermore, T cells that
had been stimulated in the presence of the agonistic anti-
CD40 mAb in vivo were able to produce much more IFN- 
and IL-2 upon brief stimulation with SIINFEKL peptide
(Fig. 2 B, compare black and gray profiles). In vitro restim-
ulation with antigen is usually used to establish that T cells
have been primed (rather than tolerized as we will show
below) by the administration of OVA-loaded splenocytes
in vivo. Indeed, the explanted T cells rapidly down-regu-
lated CD62L and up-regulated CD25 when rechallenged
with antigen in culture (Fig. 2 C), as occurred when T cells
were stimulated in vivo in the presence of the CD40 stim-
ulus (Fig. 2 A). Therefore, restimulation in culture can
change the properties of T cells from those observed during
responses in vivo in the steady state.
Deletion of T Cells Responding to Cell-associated Antigens
Presented by DCs in the Steady State. The fate of the OT-I
T cells responding to OVA presented by DCs in vivo
changed significantly when mice were examined at 9–14 d.
Although T cells initially (days 2 and 3) proliferated ac-
tively in response to presentation of dying cells by DCs,
deletion was observed at later time points (Fig. 3 A, com-
pare black and gray bars). In contrast, when OVA-loaded
Table I. Maturation of DCs by Anti-CD40
Geometric mean fluorescence intensity
CD8  DCs CD8  DCs
PBS TAP / 
TAP / 
plus
anti-CD40 PBS TAP / 
TAP / 
plus
anti-CD40
FITC-isotype 6 7 7 2 2 3
FITC CD80 26 25 46 21 21 29
FITC CD86 17 18 51 66 21
FITC CD25 8 8 10 3 3 4
FITC CD40 32 35 104 24 25 50
FITC MHC II 88 98 182 84 93 118
Biotin-isotype 3 3 3 2 2 3
Biotin CD119 46 42 7 114 115 43
The state of maturation was monitored by surface markers of splenic DC
subsets in mice given PBS or osmotically shocked cells 20 h earlier, in
the absence or presence of agonistic anti-CD40 antibody. Spleen low
density cells were prepared from the mice and stained with CD11c-PE
and CD8-Cy-Chrome™ followed by either FITC-conjugated mAbs
(MHC II, CD25, 40, 80, and 86) or biotinylated CD119 and avidin-
APC. Data are geometric mean fluorescence intensity for each mAb
from three similar experiments. The data with anti-CD40 ( 2-fold
changes in bold) were identical in the presence (shown here) or absence
(not shown) of injected dying cells.
Figure 2. The early response, by surface phenotype and cytokine pro-
duction, of OT-I T cells proliferating in response to dying cells in the ab-
sence or presence of anti-CD40 maturation. (A) Proliferation and surface
phenotype of 3   106 CFSE-labeled, CD45.1  OT-I T cells 3 d after in-
jection of OVA-loaded TAP /  splenocytes   100  g anti-CD40 mAb
intraperitoneally. Black and white arrows represent CD62Lhigh and
CD62Llow populations, respectively. (B) As in A, but the day 3 respond-
ing splenocytes were restimulated with OVA peptide (SIINFEKL) for 4 h
at 37 C with 5  g/ml BFA. The cells were stained for CD8 and CD45.1
as in A, and intracellular IFN-  and IL-2 identified with mAb after fixa-
tion and permeabilization. (C) Activation of OT-I cells by tissue culture
in the absence or presence of restimulation by SIINFEKL pulsed spleno-
cytes for 4 h. The data shown are representative of three experiments.1095 Liu et al. Brief Definitive Report
TAP /  splenocytes were coadministered with anti-
CD40, there was a prolonged expansion of the injected
CD45.1 bearing OT-I T cells in spleen, lymph node, and
blood (Fig. 3, gray bars). At day 10, the majority of the T
cells, expanded by the combination of OVA/TAP / 
splenocytes and anti-CD40, were expressing high levels of
the CD62L homing receptor, but some cells in the spleen
and blood were still CD62Llow (data not depicted). As a
control, the response of OT-I to an injection of TAP / 
cells loaded with nonspecific hen egg lysozyme protein
(HEL) was monitored. There was no expansion of the
OVA-specific OT-I cells relative to the PBS control, even
with anti-CD40 maturation, but the OT-I cells persisted
10 d (Fig. 3). As a second control for the specificity of
OT-I T cell deletion, we cotransferred F5 T cells specific
for an influenza peptide. The cotransferred F5 T cells re-
mained in blood, LN, and spleen while the OT-I T cells
were deleted in mice that received TAP/OVA (data not
depicted). Therefore, in the absence of maturation stimuli,
there is an initial vigorous T cell response to OVA pre-
sented by DCs and this is followed by antigen-specific T
cell deletion.
DC Presentation of Dying Cells Leads to Systemic Unrespon-
siveness to OVA Challenge with CFA. To determine if sys-
temic tolerance had been induced by DCs presenting cell-
associated antigen in the steady-state, we rechallenged the
mice with OVA in CFA. Mice were injected with OVA-
charged splenocytes either once (day –6) or twice (day –6
and 0), and 9 d later challenged with OVA in CFA. In
mice given TAP /  splenocytes without OVA protein, a
strong immune response was evident 3 d after the challenge
with OVA in CFA, by three criteria (Fig. 4 A, top row).
These were (a) increased OT-I T cell numbers in the
lymph nodes draining the site of OVA/CFA injection, (b)
strong proliferation to OVA challenge in culture, and (c)
the appearance of many IFN- –secreting cells in ELISPOT
assays. In contrast, mice exposed to one or two doses of
OVA-bearing splenocytes became unresponsive to chal-
lenge with CFA/OVA (Fig. 4 A). This tolerance was anti-
gen specific, as coadministered F5 TCR transgenic cells
Figure 3. Contrasting survival of OT-I T cells responding to DCs pre-
senting OVA-loaded splenocytes in the absence or presence of anti-CD40
maturation. As in Fig. 2, the proportion of responding OT-I T cells
(CD45.1  CD8 ) was measured at 3 d (black) or 10 d (gray) as a percent-
age of CD8  cells in spleen and subcutaneous lymph nodes (means of 4–5
experiments) or as a proportion of total blood cells (2–3 experiments).
Figure 4. Tolerance of mice given OVA-loaded TAP /  splenocytes
to OVA challenge with CFA. (A) 2 d after injection of 0.3   106 OT-I T
cells, B6 mice were injected with 25   106 OVA-loaded or unloaded
TAP /  splenocytes intravenously. Some mice were given OVA-loaded
TAP /  splenocytes once (day –6) and others twice (days –6 and 0). 9 d
after the last injection of OVA-loaded TAP /  splenocytes, the mice
were challenged with OVA in CFA, and total numbers of CD8 
CD45.1  OT-I cells in draining (brachial) and distal (inguinal) nodes
were measured by FACS® (left) as in Fig. 3. Enriched CD8  T cells using
magnetic microbeads® also were cocultured with the graded doses (inset)
of SIINFEKL-pulsed spleen cells after  -irradiation at 15 Gy. T cell pro-
liferation was measured by 3H-TdR uptake at 38–48 h (middle), and
IFN- –secreting cells by ELISPOT at 36 h (right). (B) Immunity devel-
ops if OVA-loaded splenocytes are presented along with anti-CD40 ago-
nistic antibody, assessed as in B with ELISPOT (right panel) and T cell
proliferation (38–48 h; left panel). The data in A and B are representative
of three experiments.1096 DC-induced Peripheral Tolerance After Uptake of Dying Cells
specific for a viral peptide (see Fig. 1 E) were not deleted
(data not depicted).
To determine if the systemic tolerance induced by dying
cells could be converted to immunity, we compared mice
injected with OVA-loaded splenocytes in the absence or
presence of anti-CD40 and then challenged with OVA in
CFA. If the mice had been exposed to OVA/TAP /  sple-
nocytes in the presence of anti-CD40, they responded vig-
orously to challenge with antigen in strong adjuvant, i.e.,
the T cells would proliferate and form IFN- –producing
ELISPOTS (Fig. 4 B). In summary, DC presentation of
OVA from dead cells to MHC class I–restricted OT-I cells
leads to tolerance in the steady state, but immunity if the
DCs are matured with anti-CD40.
Discussion
In the absence of acute inflammation and infection, most
DCs in vivo are functionally immature, capable of captur-
ing antigens but lacking many specializations needed to in-
duce immunity (for a review, see reference 17). Matura-
tion, a term designed to describe DC differentiation that
results in immunity (18, 19), takes place under several situ-
ations, particularly exposure to microbial pathogens that
signal DCs through Toll-like receptors (20). During matu-
ration, DCs produce large amounts of cytokines like IL-12
and up-regulate several B7 and TNF/TNF-R family mole-
cules. However, a frequent consequence of infection is the
death of infected cells as well as adjacent self-tissues. There-
fore, when DCs are capturing pathogens, they are also cap-
turing and presenting antigens from dying cells and the
presentation is particularly efficient. This dilemma, that
DCs will efficiently present self-antigens during infection,
has given rise to a new proposal for the maintenance of
self-tolerance (2, 3) evaluated here. We find that the cap-
ture of dying self-cells by DCs in the steady state leads to
tolerance, thereby allowing subsequent responses to focus
on microbial versus self antigens.
It may seem surprising that dying cells induce tolerance
since similar cells have been used previously to study im-
mune priming. However, prior studies differed in two po-
tentially important ways. First, the injected OVA-laden sple-
nocytes contained DCs that rapidly mature upon removal
from an animal (21); our use of dying TAP /  splenocytes
allowed presentation to take place primarily on recipient
nonmaturing DCs in the steady state (Fig. 1, Table I). Sec-
ond, prior studies documented priming using in vitro restim-
ulation assays performed shortly after the injection of OVA-
charged splenocytes. We found that proliferating T cells
early on in the peripheral tolerance process could be acti-
vated upon removal from the animal (Fig. 2 C), e.g., because
of exposure to mature DCs during the culture assay. This in
vitro assay could then give a false impression of priming,
whereas if the T cells remained in vivo, they eventually
would be deleted and the mice would become tolerant.
The induction of tolerance by DCs capturing dying sple-
nocytes is functionally similar to the peripheral tolerance
observed in mice expressing antigens as transgenes on pan-
creatic islet   cells (22, 23). In these elegant studies, anti-
gens were presented in the draining pancreatic lymph node
by “tolerogenic” DCs (11, 24, 25). One of the ways in
which this cross presentation could begin would be for
DCs to capture   cells dying during normal islet turnover.
DCs can capture dying intestinal epithelial cells in the lam-
ina propria (10), while Hugues et al. induced the limited
death of   cells with streptozoticin and observed decreased
responses to   cells (10). In studies submitted during the
course of this work, animals became tolerant when injected
with DCs from mice exposed to hapten-modified spleno-
cytes (26). Our findings provide direct evidence that the
capture of dying cells by DCs results in antigen-specific de-
letional tolerance in situ, and demonstrate that a single in-
jection with low levels of a cell-associated protein,  150
ng/mouse, can delete  106 CD8  T cells. Likewise, small
amounts of protein, when delivered via the DEC-205 re-
ceptor to DCs in vivo, result in deletional tolerance of
CD4  T cells (27). In prior studies on the induction of pe-
ripheral tolerance, in which antigens were not targeted to
DCs, it was necessary to use much larger doses of antigen
( 100  g/mouse) and in the form of preprocessed anti-
genic peptides (28–30). The induction of peripheral toler-
ance extends prior evidence from the thymus (4, 5) that
DCs help to define immunologic self.
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